Home » Halozyme Doses Patient for Clinical Trial With Roche
Halozyme Doses Patient for Clinical Trial With Roche
Halozyme Therapeutics, Inc, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced that the first patient was dosed in a Phase I pharmacokinetic clinical trial using Enhanze Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.
MSN
MSN
Upcoming Events
-
07May
-
14May
-
30May